Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver

Table 1 Demographic and clinical characteristics of the patients

Number of patients	100
SVR/non-SVR	63/37
Age (yr)	56.3 ± 7.4
Male/female	39/61
Genotype (1b/2a/2b)	50/17/33
HCV RNA (log IU/mL)	5.87 ± 0.95
Aspartate aminotransferase (< 30 IU/L)	51.1 ± 35.9
Alanine aminotransferase (< 30 IU/L)	61.8 ± 53.0
γ-glutamyl transpeptidase (< 50 IU/L)	50.7 ± 58.9
Fe (male, 55-200 μg/dL; female, 45-180 μg/dL)	130.3 ± 64.2
Unsaturated iron binding capacity (105-300 μg/dL)	215.1 ± 84.2
WBC (4000-9000/μL)	4987 ± 1303
Hemoglobin (male, 13-17; female, 11-15 g/dL)	13.6 ± 1.5
Platelet (11 × 104-35 × 104/μL)	19.6 ± 6.7
Dose reduction of ribavirin (%)	47

Normal range is presented in parenthesis. Measured values are shown in mean ± SD. SVR: Sustained virological response; HCV: Hepatitis C virus; WBC: White blood cell.